Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Preferred Stock Liabilities (2018 - 2019)

Exagen filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $121.0 million for Q2 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $121.0 million in Q2 2019 year-over-year; TTM through Jun 2019 was $121.0 million, a N/A change, with the full-year FY2018 number at $1.5 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $121.0 million in Q2 2019 for Exagen, up from $114.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $121.0 million in Q2 2019 to a low of $1.5 million in Q4 2018.